Breakthroughs in hepatitis C research: from discovery to cure | Nature Reviews Gastroenterology & Hepatology
Sofosbuvir/Velpatasvir for Patients With Chronic Genotype 3 HCV Infection With Compensated Cirrhosis: an Integrated Analysis of Phase 2 and Phase 3 Clinical Trials
Hepatitis C Archives -
Current progress in development of hepatitis C virus vaccines | Nature Medicine
Hepatitis C | HCV | MedlinePlus
Inovia to begin hepatitis C clinical trial Labmate Online
Clinical Trials 101: Your Guide to Hepatitis C & Clinical Research
Behavioral interventions to improve population health outreach for hepatitis C screening: randomized clinical trial | The BMJ
%20Infections:%0A%0ARibavirin%20(RBV)%20for%20Hepatitis%20C.png?md=1 "Ribavirin (RBV) for Hepatitis C Clinical Trial 2023 | Power")
Ribavirin (RBV) for Hepatitis C Clinical Trial 2023 | Power
HCV-Trials.com : A regularly updated website with all most recent clinical trials data in HCV infection
Direct-acting agents to treat hepatitis C in phase 2 and 3 clinical... | Download Table
AbbVie's 8 week trial speedy and successful for 98% of Hep C patients
The Bulletin of WHO publishes an article on the thematic study: hepatitis C by the Access to Medicine Foundation | Access to Medicine Foundation
New affordable hepatitis C combination shows 97% cure rate | aidsmap
Chapter - Direct-Acting Antiviral Drugs for Treatment of Hepatitis C Virus Infection-Clinical Trials Data and Chemistry of NS3/4a Protease Inhibitors | Bentham Science
Gastroenterology Clinical Trials - Dallas, TX | GI Alliance
Hepatitis C: charting the clinical trial landscape over the last decade - Clinical Trials Arena
Viruses | Free Full-Text | Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance
Clinical trials in HCV vaccine. All data below obtained from... | Download Table
Challenges in hepatitis C virus vaccine research. Graphical... | Download Scientific Diagram
Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice - ScienceDirect
![A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial - The Lancet Gastroenterology & Hepatology](https://www.thelancet.com/cms/asset/5f70e2ed-642c-49e3-9230-5eba1fc35e56/gr1.gif "A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial - The Lancet Gastroenterology & Hepatology")
A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial - The Lancet Gastroenterology & Hepatology
Current and Future Therapies for Hepatitis C Virus Infection | NEJM
